Innovative medicine for treatment of people with Mucopolysaccharidosis was delivered in Ukraine

Mar 2, 2018

Photo credit: UNDP in Ukraine / Andriy Krepkikh

Recently Okhmatdyt Hospital received a medicine for treatment of patients with Mucopolysaccharidosis. This is the first time that Ukraine with budget funds buys medicines for patients with IVA type of this disease. Previously patients were forced to treat at their own expense.

The value of the medicines is 120 mln Hryvnia. Elosulfase alpha is an innovative medicine produced by a US-based manufacturer and was first registered in the USA in 2014.

Mr. Janthomas Hiemstra, UNDP Country Director in Ukraine, commented: "It is important that every year Ukraine is ensuring more patients receive life-saving treatment, especially for diseases where treatment didn’t exist just a few years ago. We also should remember that sustaining balance between innovative and generic medicines is key for efficient spending of budget funds.”

It’s not often that innovative medicines for treatment of orphan diseases are developed as they require expensive raw materials and lengthy clinical trials. At the same time, there are very few patients to cover the expenses with volume. Global statistics of people with Mucopolysaccharidosis is 1:20000; in Ukraine there are 54 people registered with this disease.

 “Orphan or rare, non-curable diseases require patients to receive permanent and very costly supporting therapy,” said Tetyana Kulesha, Head of the Council for the NGO “Orphan diseases of Ukraine”. “That is why it is so important that the state doesn’t leave patients on their own against the disease and ensures financial support for their treatment.”

Media inquiries:

UNDP Around the world

You are at UNDP Ukraine 
Go to UNDP Global